Payment overview · 2025
General Payments
$264.12
3 reported records · 3 companies
Healthcare provider profile · identity verified
Margo Lashae Thomas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ALEXANDRIA, LA · NPI 1114138658
Verified facts
What the public records show
CMS Open Payments records show Margo Lashae Thomas, M.D. received $264.12 in general payments during 2025 across 3 reported records.
Novo Nordisk Inc accounted for 47.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $125.01 | 47.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.98 | 47.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.13 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $264.12 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 126 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 156 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
200 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
126 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
156 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 938 | 268 |
| Amlodipine Besylate | Amlodipine Besylate | 635 | 185 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 512 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 512 | 142 |
| Losartan Potassium | Losartan Potassium | 506 | 132 |
| Alprazolam | Alprazolam | 502 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 469 | 141 |
| Gabapentin | Gabapentin | 464 | 153 |
| Potassium Chloride | Potassium Chloride | 374 | 110 |
| Warfarin Sodium | Warfarin Sodium | 355 | 63 |
| Lisinopril | Lisinopril | 353 | 98 |
| Metformin Hcl | Metformin Hcl | 340 | 92 |
| Omeprazole | Omeprazole | 324 | 98 |
| Furosemide | Furosemide | 316 | 91 |
| Clopidogrel | Clopidogrel Bisulfate | 292 | 86 |
| Montelukast Sodium | Montelukast Sodium | 284 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 273 | 69 |
| Tramadol Hcl | Tramadol Hcl | 268 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 266 | 72 |
| Pravastatin Sodium | Pravastatin Sodium | 254 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 253 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 79 |
| Ezetimibe | Ezetimibe | 233 | 65 |
| Simvastatin | Simvastatin | 224 | 67 |
| Trazodone Hcl | Trazodone Hcl | 223 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 59 |
| Alendronate Sodium | Alendronate Sodium | 207 | 65 |
| Carvedilol | Carvedilol | 200 | 58 |
| Jardiance | Empagliflozin | 200 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 184 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 51 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 164 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 162 | 22 |
| Ozempic | Semaglutide | 156 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 63 |
| Nifedipine Er | Nifedipine | 150 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 59 |
| Pregabalin | Pregabalin | 143 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 139 | 55 |
| Allopurinol | Allopurinol | 134 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 131 | 45 |
| Metformin Hcl Er | Metformin Hcl | 127 | 34 |
| Mounjaro | Tirzepatide | 126 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 40 |
| Famotidine | Famotidine | 118 | 37 |
| Linzess | Linaclotide | 117 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 116 | 18 |
| Clonazepam | Clonazepam | 110 | 16 |
| Meloxicam | Meloxicam | 110 | 45 |
| Glimepiride | Glimepiride | 106 | 30 |
| Sertraline Hcl | Sertraline Hcl | 106 | 24 |
| Memantine Hcl | Memantine Hcl | 102 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 31 |
| Meclizine Hcl | Meclizine Hcl | 94 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 21 |
| Eliquis | Apixaban | 92 | 22 |
| Fluconazole | Fluconazole | 91 | 42 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 88 | 33 |
| Clonidine Hcl | Clonidine Hcl | 79 | 25 |
| Farxiga | Dapagliflozin Propanediol | 78 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 18 |
| Synthroid | Levothyroxine Sodium | 73 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 19 |
| Donepezil Hcl | Donepezil Hcl | 66 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 17 |
| Trulicity | Dulaglutide | 65 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | 20 |
| Atenolol | Atenolol | 62 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 15 |
| Vascepa | Icosapent Ethyl | 60 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 57 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 14 |
| Ibuprofen | Ibuprofen | 56 | 15 |
| Diazepam | Diazepam | 54 | 13 |
| Prednisone | Prednisone | 54 | 39 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 14 |
| Promethazine Hcl | Promethazine Hcl | 52 | suppressed |
| Valsartan | Valsartan | 52 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 48 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 47 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 35 |
| Temazepam | Temazepam | 46 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 45 | 14 |
| Chlorthalidone | Chlorthalidone | 45 | 12 |
| Novolog Flexpen | Insulin Aspart | 45 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 14 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Mupirocin | Mupirocin | 42 | 32 |
| Nystatin | Nystatin | 41 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 15 |
| Lovastatin | Lovastatin | 40 | 12 |
| Spironolactone | Spironolactone | 40 | 12 |
| Cefuroxime | Cefuroxime Axetil | 39 | 35 |
| Celecoxib | Celecoxib | 39 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 39 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Baclofen | Baclofen | 37 | 12 |
| Estradiol | Estradiol | 37 | 11 |
| Glipizide | Glipizide | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 32 |
| Topiramate | Topiramate | 35 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 34 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | 12 |
| Buspirone Hcl | Buspirone Hcl | 32 | 13 |
| Lidocaine | Lidocaine | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 29 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Calcitriol | Calcitriol | 30 | 11 |
| Ondansetron Odt | Ondansetron | 30 | 17 |
| Torsemide | Torsemide | 30 | 12 |
| Olanzapine | Olanzapine | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 29 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 29 | 11 |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | 16 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 11 |
| Movantik | Naloxegol Oxalate | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ingrezza | Valbenazine Tosylate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Constulose | Lactulose | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
| Vivelle-Dot | Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $264.12 · 3 records | Novo Nordisk Inc | MOUNJARO, Ozempic, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error